Why the Australian Clinical Labs (ASX:ACL) share price soared 5% today

Australian Clinical Labs has impressed shareholders on its improved FY21 outlook. Here are the details

| More on:
Lab technician analyses a sample in a laboratory for a clinical trial

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Australian Clinical Labs Ltd (ASX: ACL) share price climbed to a new high of $3.88 during trading today. This follows the pathology service provider's announcement that it has upgraded its earnings forecast for the 2021 financial year.

At close of trading, the company's shares had lowered slightly to $3.74, but were still up 5.35%.

What did Australian Clinical Labs announce?

Investors drove up the Australian Clinical Labs share price after the company provided an improved performance outlook.

In a statement to the ASX, the company stated it had exceeded its original projections in the prospectus released in late April.

The revised FY21 guidance is forecasting total revenue of between $657.7 million and $663.3 million. This is up to 3% higher than the $647 million projected in the prospectus.

Earnings before interest, tax, depreciation and amortisation (EBITDA) is also expected to surge by between $217.4 million and $222.3 million. The adjusted result reflects a lift of up to 7% on the $207.7 million assumed in April.

And lastly, net profit after tax (NPAT) is predicted to jump by between $82 million and $85.4 million. In comparison to the $74.5 million stated in the prospectus, this is an increase of up to 15%.

Australian Clinical Labs noted the boost in numbers was driven by revenue growth, with costs kept in line or below the prospectus forecasts. In addition, the prospectus contained just 7 months of actual result, with the 5 remaining months based on company projections.

Australian Clinical Labs CEO and executive director Melinda McGrath commented:

We are pleased with the positive momentum across the business despite the continued uncertainties arising from COVID-19. It is anticipated that the FY21 pro-forma NPAT will be 10% to 15% higher than the FY21 forecast disclosed in the prospectus.

Share price snapshot

Australian Clinical Labs is a leading provider of pathology services in Australia. The company has 86 laboratories accredited by the National Association of Testing Authorities and performs a comprehensive range of services for doctors, patients and corporate clients. 

Since listing on the ASX in mid-May at a price of $4 apiece, Australian Clinical Labs shares are slightly down.

Australian Clinical Labs has a market capitalisation of roughly $760 million, with more than 201 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 114% in a year, why is the Pro Medicus share price leaping higher again on Thursday?

Pro Medicus shares are back in form today and leaping ahead. Here’s why.

Read more »

Two doctors give the thumbs up to an x-ray
Healthcare Shares

Buying the dip: $10,000 invested in Pro Medicus shares on 7 April is now worth…

This healthcare stock has boomed over the past month. 

Read more »

Two doctors wearing white coats look closely at a medical imaging x-ray as the share prices of ASX 200 healthcare shares improve in FY23
Healthcare Shares

Pro Medicus shares climb 33% in less than a month, have I missed the dip?

Pro Medicus shares have soared. Is it the right time to invest?

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords share just rocketed 19% on BIG news

Investors are sending this ASX All Ords share flying on Monday. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Healthcare Shares

Why is this ASX All Ords stock surging 14% today?

This stock is starting the week strongly. But why? Let's find out.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

Guess which ASX All Ords stock is rocketing 58% on big US news

What is getting investors excited today? Let's find out.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 reasons to buy this quality ASX 200 healthcare share today

A leading expert expects this outperforming ASX 200 healthcare share will keep running hot.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Brokers tip 4 ASX 200 healthcare shares to buy now

Healthcare is a defensive sector that can provide useful cover for investors when the market is volatile.

Read more »